Bank of New York Mellon’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.6M | Buy |
|
|||||
|
2025
Q1 | $13.3M | Sell |
|
|||||
|
2024
Q4 | $13.9M | Sell |
|
|||||
|
2024
Q3 | $13.5M | Sell |
|
|||||
|
2024
Q2 | $12.3M | Sell |
|
|||||
|
2024
Q1 | $10.8M | Sell |
|
|||||
|
2023
Q4 | $11.1M | Buy |
|
|||||
|
2023
Q3 | $8.73M | Sell |
|
|||||
|
2023
Q2 | $10.9M | Buy |
|
|||||
|
2023
Q1 | $11.1M | Sell |
|
|||||
|
2022
Q4 | $10.5M | Sell |
|
|||||
|
2022
Q3 | $14M | Sell |
|
|||||
|
2022
Q2 | $14.7M | Sell |
|
|||||
|
2022
Q1 | $20.7M | Sell |
|
|||||
|
2021
Q4 | $29.6M | Buy |
|
|||||
|
2021
Q3 | $26.3M | Sell |
|
|||||
|
2021
Q2 | $24.9M | Buy |
|
|||||
|
2021
Q1 | $27.5M | Sell |
|
|||||
|
2020
Q4 | $19.6M | Sell |
|
|||||
|
2020
Q3 | $19.9M | Sell |
|
|||||
|
2020
Q2 | $24.9M | Sell |
|
|||||
|
2020
Q1 | $17M | Sell |
|
|||||
|
2019
Q4 | $27.8M | Sell |
|
|||||
|
2019
Q3 | $30M | Sell |
|
|||||
|
2019
Q2 | $39.2M | Sell |
|
|||||
|
2019
Q1 | $43.3M | Sell |
|
|||||
|
2018
Q4 | $55.3M | Sell |
|
|||||
|
2018
Q3 | $137M | Sell |
|
|||||
|
2018
Q2 | $107M | Sell |
|
|||||
|
2018
Q1 | $85.8M | Sell |
|
|||||
|
2017
Q4 | $72.1M | Sell |
|
|||||
|
2017
Q3 | $71.7M | Sell |
|
|||||
|
2017
Q2 | $68M | Buy |
|
|||||
|
2017
Q1 | $58.5M | Buy |
|
|||||
|
2016
Q4 | $54.2M | Buy |
|
|||||
|
2016
Q3 | $49.6M | Sell |
|
|||||
|
2016
Q2 | $58.3M | Sell |
|
|||||
|
2016
Q1 | $63.2M | Buy |
|
|||||
|
2015
Q4 | $59M | Sell |
|
|||||
|
2015
Q3 | $52.4M | Buy |
|
|||||
|
2015
Q2 | $61.3M | Buy |
|
|||||
|
2015
Q1 | $29.4M | Buy |
|
|||||
|
2014
Q4 | $11.1M | Sell |
|
|||||
|
2014
Q3 | $10M | Buy |
|
|||||
|
2014
Q2 | $12.7M | Buy |
|
|||||
|
2014
Q1 | $13.3M | Buy |
|
|||||
|
2013
Q4 | $10.1M | Buy |
|
|||||
|
2013
Q3 | $4.18M | Sell |
|
|||||
|
2013
Q2 | $4.11M | Buy |
|